Not provided
Not provided
Not provided
Not provided
Not provided
had been finished
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is the first evidence based work evaluated the systemic use of glucosamine as an adjunctive therapy to closed mechanical debridement in chronic periodontitis. The use of glucosamine sulphate was correlated with clinical outcomes and IL1-β level in the GCF of patients with moderate to advanced chronic periodontitis
Targeting the inflammatory response may be a rational approach to the medical treatment of chronic periodontitis. Glucosamine sulphate (GS) was proven to have anti-inflammatory actions with minimal side effect profile. Objectives; The main objectives of this study were to evaluate clinically the efficacy of GS; as a novel adjunctive host modulating agent in periodontal therapy and to investigate its effect on gingival crevicular fluid (GCF) level of IL-1β. Methods; Forty patients with moderate to severe chronic periodontitis (CP) were included in this study. They were randomly divided into two groups. Group I (G1) patients (n=20) received 500 mg GS capsules three times daily for 3 months following full mouth scaling and root planing (SRP), while group II (G2) patients (n=20) received a placebo for the same period following full mouth SRP. Clinical periodontal parameters and GCF IL-1β levels were analyzed at baseline and 3 months following therapy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| glucosamine sulphate capsules | Active Comparator | 500 mg Glucosamine Compound, three times daily for 3 months following initial cause related therapy. |
|
| lactose capsules | Placebo Comparator | lactose capsules three times daily for 3 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| glucosamine sulphate | Drug | group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy |
| Measure | Description | Time Frame |
|---|---|---|
| gingival crevicular fluid IL-1β level | baseline and after three months of Glucosamine Sulphate administration | 0-3 months |
| Measure | Description | Time Frame |
|---|---|---|
| probing depth | the distance from the gingival margin to the base of the pocket was measured at baseline and 3 months after drug administration | 0-3 months |
| clinical attachment level | distance from cemento-enamel junction and base of the pocket was measured at baseline and 3 months after drug administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ahmaed Y Gamal | Ainshams University | Principal Investigator |
| Hala A Elela, professer | Ainshams University | Principal Investigator |
| Mai S Attia, Lecturer | Al-Azhar University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ainshams University | Cairo | 11566 | Egypt |
Not provided
| ID | Term |
|---|---|
| D055113 | Chronic Periodontitis |
| ID | Term |
|---|---|
| D010518 | Periodontitis |
| D010510 | Periodontal Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005944 | Glucosamine |
| D007785 | Lactose |
| ID | Term |
|---|---|
| D006595 | Hexosamines |
| D000606 | Amino Sugars |
| D002241 | Carbohydrates |
| D004187 | Disaccharides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| lactose capsules | Drug |
|
| 0-3 months |
| gingival index | gingival inflammation was measured by gingival index at baseline and 3 months after drug administration. | 0-3 months |
| plaque index | plaque deposits was measured by plaque index at baseline and 3 months after drug therapy | 0-3 months |
| D002908 |
| Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009844 |
| Oligosaccharides |
| D011134 | Polysaccharides |
| D000073893 | Sugars |